BioAge Labs Inc. (BIOA) vs Lyell Immunopharma, Inc. (LYEL)
A side-by-side comparison of BioAge Labs Inc. and Lyell Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BIOA
BioAge Labs Inc.
$6.30HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
LYEL
Lyell Immunopharma, Inc.
$8.78HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — BIOA vs LYEL
growth of $100 · dividends reinvested · last 2yBIOA -65.3% (-41.1%/yr)LYEL -70.2% (-45.4%/yr)BIOA compounded faster over this window
BIOA LYEL
BIOA vs LYEL: by the numbers
- •BIOA is the larger company ($237M vs $215M market cap).
- •Both run net losses; BIOA's is the smaller (-912.25% vs -920285.19% net margin).
Metrics side by side
Valuation
| Metric | BIOA | LYEL |
|---|---|---|
| P/S ratio | 22.89 | 7967.64 |
| P/B ratio | 0.63 | 0.92 |
Profitability
| Metric | BIOA | LYEL |
|---|---|---|
| Gross margin | 99.39% | -31952.78% |
| Operating margin | -1026.28% | -566038.89% |
| Net margin | -912.25% | -920285.19% |
| ROE | -25.20% | -106.27% |
| ROIC | -28.14% | -70.80% |
Growth (annualized)
| Metric | BIOA | LYEL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -68.32% |
| Total return CAGR (5Y) | N/A | -48.18% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.